Bristol-myers Squibb Compnay

Janssen Pharmaceutica Nv

Other

Janssen Biotech, Inc.

Marco Gottardis

Joan Carboni

Ray Camphausen

Ricardo Attar

Linda Snyder

Rebecca Hawkins

Douglas H Yamada

Stuart Emanuel

Martin C Wright

Linda Engle

Eric Steven Furfine

Ginger Chao Rakestraw

H Nicholas Marsh

Irvith M Carvajal

Mark E Salvati

Matthew V Lorenzi

John N Feder

James Aaron Balog

Stanley Richard Krystek, Jr

Chongqing Sun

Liana M Lee

Manuel Sepulveda

Hinrich Gronemeyer

John S Sack

Dacia A Pickering

Donald G Jackson

Vinod Krishna

Vipul Bhargava

Roberto Weinmann

Rogelio L Martinez

Fei Huang

Michel Lanotte

Xia Han

Kurtis Bachman

David J Pocalyko

Guido Leoni

Ashok Ramesh Dongre

Dan You

Thomas Spires

G&eacute;rard Benoit

Ginger Chao

Warren Hurlburt

Derick Siegel

Pegah Safabakhsh

Gayle M Wittenberg

Darryl L Davis

Douglas Michael Robinson

Jiwen Chen

Rameh Hafezi

Disclosed are methods of treating prostate cancer by administering niraparib to a human in need thereof.

Methods of treating prostate cancer

The disclosure relates to prostate neoantigens, polynucleotides encoding them, vectors, host cells, recombinant virus particles, vaccines comprising the neoantigens, proteinaceous molecules binding the prostate neoantigens, and methods of making and using them.

Prostate neoantigens and their uses

Method of treating prostate cancer

The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.

Bispecific EGFR/IGFIR binding molecules

The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.

Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins

Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules

Multivalent fibronectin based scaffold domain proteins

Method of treating cancer by administering EGFR and EGFR/IGFIR binding molecules

IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.

Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators

Growing community of inventors

Princeton, NJ, United States of America

Marco Gottardis